GDRX

GoodRx Holdings, Inc.

Fundamental data last updated:November 6, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Medical - Healthcare Information Services

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

Pending Announcement

Business Summary

GoodRx Holdings, Inc. provides American consumers with essential resources and tools to compare and ultimately lower the cost of their prescription medications. The company operates a digital platform dedicated to price comparison, delivering customized, geographically tailored prescription pricing. It also grants access to special, negotiated rates through unique GoodRx codes, which can be utilized for savings on prescriptions throughout the entire United States. Beyond this core offering, the firm also extends its portfolio to include subscription services, programs designed for pharmaceutical manufacturers, and telehealth capabilities. GoodRx additionally collaborates with pharmacy benefit managers, entities responsible for managing drug formularies and overseeing prescription transactions, including the critical task of setting prices between consumers and pharmacies. The company was founded in 2015 and maintains its principal office in Santa Monica, California.

 


Analyze GDRX on TradingView

VALUATION

P/E

66.16

Market Cap ($M USD)

$1.19B

Forward P/E

11.47

PEG

-4.18

PRICE TO SALES

1.51

PRICE TO BOOK

1.82

EV / EBITDA

8.37

5-Year Average P/E

Free Cash Flow Yield

12.28%

DCF Value

$4.98

Graham Number

$1.43

Price to FCF

8.15

EV to FCF

9.81

Earnings Yield

1.38%

FCF Yield

12.28%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

$0.05

Next Year EPS Growth Estimate

$0.30

Next Year Revenue Growth Estimate

$799.58M

Return on Equity (ROE)

2.61%

FREE CASH FLOW

Operating Margin

10.25%

Debt-to-Equity

0.83

Piotroski F-Score

7

Altman Z-Score

0.26

Return on Invested Capital (ROIC)

2.64%

Current Ratio

1.38

Quick Ratio

1.38

Net Debt to EBITDA

1.42

Interest Coverage

1.97

Gross Profit margin

88.05%

FCF PER SHARE

$0.43

REVENUE PER SHARE

$2.31

Analyze GDRX on TradingView

Gainseekers Quantitative Analysis

Summary

The market seems to be undervaluing GoodRx Holdings, Inc. Based on the data at the time of this analysis, the stock traded below its DCF value and Graham Number, suggesting a potential mispricing. The absence of a Forward P/E and a low Earnings Yield indicate limited growth expectations, while the Altman Z-score of 0.23 raises red flags about financial distress. Despite these concerns, the company’s valuation metrics like Price/Sales and EV to EBITDA suggest a bargain for value hunters.

AI Exposure / Tech Reliance

Operating in the Medical - Healthcare Information Services industry, GoodRx is well-positioned to leverage AI and tech advancements. Its focus on healthcare information services aligns with the growing trend of digital health solutions. This adaptability could enhance its competitive edge in a tech-driven landscape.

The Bull Case

For the discerning value or GARP investor, GoodRx presents an intriguing opportunity. With a solid ROIC of 6.80% and a robust FCF Yield of 13.01%, the company demonstrates efficient capital allocation and cash generation. The Piotroski F-Score of 6 indicates reasonable financial health, while an impressive Gross Profit Margin of 89.32% underscores its pricing power. These metrics suggest a company capable of delivering shareholder value through strategic execution.

The Bear Case

However, structural risks loom large. The Altman Z-score signals potential financial instability, and the Earnings Yield of just 2.97% reflects a lack of compelling income generation. Despite a low Debt/Equity ratio, the stock's Price/Book and Price/Sales ratios suggest it may not be the deep value play it appears. Additionally, trading close to its 52-week low could indicate market skepticism about its growth prospects.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Hold

Average Analyst Price Target

$4.19

Institutional Ownership %

1-Year Beta

1.69

Insider Buying % (6 Mo)

Distance to 52-Week High

11.78%

Distance to 52-Week Low

49.14%

EARNINGS SURPRISE %

0.40%

50-DAY SMA

$3.44

200-DAY SMA

$2.81

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.